CereScan First in Rocky Mountain Region to Offer New Test to Help Identify Parkinson's Disease
GE Healthcare's DaTscan Can Help Give Doctors and Patients a Clearer Picture of Parkinson's and Parkinson's Syndrome
(firmenpresse) - DENVER, CO -- (Marketwire) -- 10/13/11 -- , a Denver-based brain imaging center, is the first center in the Rocky Mountain Region to offer , the first Food and Drug Administration-approved imaging agent to help diagnose patients with suspected Parkinsonian syndromes, such as Parkinson's disease -- a neurodegenerative disorder that afflicts nearly 1.5 million Americans, with an additional 50,000 to 60,000 new cases identified each year.
DaTscan, by GE Healthcare, is performed by injecting a tiny dose of a radioactive tracer, followed by a painless imaging procedure called SPECT (single photon emission computed tomography), to search for dopamine transporters (DaT). Dopamine, a brain chemical responsible for movement control, diminishes in patients with Parkinson's disease causing tremor, slowness of movement, muscle stiffness and balance problems. The tracer binds to the dopamine transporters and the scan produces images that provide visual evidence of the presence of dopamine transporters. The entire procedure requires three to four hours.
"Because medications prescribed for Parkinson's can cause serious side effects, confirming the right diagnosis is critical for a patient's treatment," said John Kelley, Chairman and CEO of CereScan. "DaTscan will help doctors determine the most effective treatment plan for each patient. The availability of this test is great news for Parkinson's patients in Colorado and the entire region."
CereScan is a national leader in neurodiagnostics, which utilizes a state-of-the-art brain imaging technology delivered in a warm, patient focused setting. Combining high definition functional brain imaging with an extensive library of clinical data, the CereScan medical team provides physicians with unmatched diagnostic insight into brain-based disorders. CereScan helps patients and their physicians, therapists and families to better understand the biological basis of their conditions and disorders. For more information visit .
Image Available:
Contact:
Jon Pushkin
Pushkin Public Relations
P: 303-733-3441
Email:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 13.10.2011 - 11:10 Uhr
Sprache: Deutsch
News-ID 1045766
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
DENVER, CO
Phone:
Kategorie:
Healthcare
Anmerkungen:
Diese Pressemitteilung wurde bisher 122 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CereScan First in Rocky Mountain Region to Offer New Test to Help Identify Parkinson's Disease
"
steht unter der journalistisch-redaktionellen Verantwortung von
CereScan (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
